Reduction of the HIV Seroconversion Window Period and False Positive Rate by Using ADVIA Centaur HIV Antigen/Antibody Combo Assay
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Early diagnosis of HIV infection reduces morbidity and mortality. Fourth-generation HIV detection assays are more sensitive because they can detect p24 antigen as well as anti-HIV antibodies. In this study, we evaluated the performance of a new fourth-generation ADVIA Centaur HIV antigen/antibody combo (CHIV) assay (Siemens Healthcare Diagnostics Inc., USA) for early detection of HIV infection and reduction of false positive rate. Methods: Four seroconversion panels were included. The third-generation ADVIA Centaur HIV 1/O/2 enhanced (EHIV) assay (Siemens Healthcare Diagnostics Inc., USA) and fourth-generation CHIV assay were used to test each panel for HIV infection. The presence of antigen was confirmed using HIV p24 antigen assay. To evaluate false-positivity and specificity, 54 HIV false-positive and HIV-negative serum samples from 100 hospitalized patients and 600 healthy subjects were included. Results: Compared to the EHIV assay, the CHIV assay had a shorter window for three of the seroconversion panels: a difference of 10 days and two bleeds in one panel, and 4 days and one bleed in the other two panels. Only 34 of the 54 (63%) samples known to yield false-positive results by EHIV assay had repeatedly yielded reactive results in the CHIV assay. One of the 600 healthy subjects had a false-positive result with the CHIV assay; thus, the specificity was 99.85% (699/700). CHIV accurately determined the reactive results for the HIV-confirmed serum samples from known HIV patients and Korea Food & Drug Administration (KFDA) panels. Conclusions: The new fourth-generation ADVIA Centaur HIV assay is a sensitive and specific assay that shortens the serological window period and allows early diagnosis of HIV infection.
Abstract
Background: Early diagnosis of HIV infection reduces morbidity and mortality. Fourth-generation HIV detection assays are more sensitive because they can detect p24 antigen as well as anti-HIV antibodies. In this study, we evaluated the performance of a new fourth-generation ADVIA Centaur HIV antigen/antibody combo (CHIV) assay (Siemens Healthcare Diagnostics Inc., USA) for early detection of HIV infection and reduction of false positive rate. Methods: Four seroconversion panels were included. The third-generation ADVIA Centaur HIV 1/O/2 enhanced (EHIV) assay (Siemens Healthcare Diagnostics Inc., USA) and fourth-generation CHIV assay were used to test each panel for HIV infection. The presence of antigen was confirmed using HIV p24 antigen assay. To evaluate false-positivity and specificity, 54 HIV false-positive and HIV-negative serum samples from 100 hospitalized patients and 600 healthy subjects were included. Results: Compared to the EHIV assay, the CHIV assay had a shorter window for three of the seroconversion panels: a difference of 10 days and two bleeds in one panel, and 4 days and one bleed in the other two panels. Only 34 of the 54 (63%) samples known to yield false-positive results by EHIV assay had repeatedly yielded reactive results in the CHIV assay. One of the 600 healthy subjects had a false-positive result with the CHIV assay; thus, the specificity was 99.85% (699/700). CHIV accurately determined the reactive results for the HIV-confirmed serum samples from known HIV patients and Korea Food & Drug Administration (KFDA) panels. Conclusions: The new fourth-generation ADVIA Centaur HIV assay is a sensitive and specific assay that shortens the serological window period and allows early diagnosis of HIV infection.
참고문헌 (22)
- UNAIDS, "AIDS epidemic update 2009", pp.2009, UNAIDS
- "Analysis of HIV/AIDS Notifications in Korea"[URL]
- 이선희, "Trends of Mortality and Cause of Death among HIV-Infected Patients in Korea, 1990-2011", Journal of Korean Medical Science, 28(1), pp.67~73 (2013), 대한의학회
- Choe PG, "Late presentation of HIV disease and its associated factors among newly diagnosed patients before and after abolition of a government policy of mass mandatory screening", JOURNAL OF INFECTION, 63, pp.60~65 (2011), W B SAUNDERS CO LTD
- Branson BM, "Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings", MMWR Recomm Rep, 55, pp.1~17 (2006)
- Mahajan VS, "Interpretation of HIV serologic testing results", Clin Chem, 56, pp.1523~1526 (2010)
- Gürtler L, "Reduction of the diagnostic window with a new combined p24 antigen and human immunodeficiency virus antibody screening assay", J Virol Methods, 75, pp.27~38 (1998)
- Busch MP, "Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure", Am J Med, 102, pp.117~124 (1997)
- Weber B, "Reduction of diagnostic window by new fourth-generation human immunodeficiency virus screening assays", J Clin Microbiol, 36, pp.2235~2239 (1998)
- Brust S, "Shortening of the diagnostic window with a new combined HIV p24 antigen and anti-HIV-1", 2, J Virol Methods, pp.2000, 90[DOI]
- Weber B, "Multicenter evaluation of a new automated fourth-generation human immunodeficiency virus screening assay with a sensitive antigen detection module and high specificity", J Clin Microbiol, 40, pp.1938~1946 (2002)
- Beelaert G, "Evaluation of a rapid and simple fourth-generation HIV screening assay for qualitative detection of HIV p24 antigen and", or antibodies to HIV-1 and HIV-2, 2010, pp.168, 218~222
- Weber B, "Multicenter evaluation of a new 4th generation HIV screening assay Elecsys HIV combi", Clin Lab, 52, pp.463~473 (2006)
- 강희정, "애보트 4세대 HIV 항원", 항체 검사 시약의 평가, 2006, pp.26(1), 39~44[DOI]
- Kwon JA, "Performance evaluation of three automated human immunodeficiency virus antigen-antibody combination immunoassays", J VIROL METHODS, 133(133), pp.20~26 (2006), Elsevier
- Butto S, "Laboratory diagnostics for HIV infection", Ann Ist Super Sanita, 46, pp.24~33 (2010)
- Song EY, "Performances of four fourth-generation human immunodeficiency virus-1 screening assays", J Med Virol, 84, pp.1884~1888 (2012)
- Pumarola T, "Performance evaluation of the ADVIA Centaur(®) HIV Ag", Ab Combo assay, 2010, pp.170, 16~20
- Erickson CP, "Influenza vaccination and false positive HIV results", N Engl J Med, 354, pp.1422~1423 (2006)
- Chao TT, "Risk factors associated with false positive HIV test results in a low-risk urban obstetric population", J Pregnancy, 2012, pp.841979~ (2012)
- Kasper DL, "Harrison’s principles of internal medicine. 18th ed" (2012), McGraw-Hill
- Miedouge M, "Analytical sensitivity of four HIV combined antigen", antibody assays using the p24 WHO standard, 2011, pp.50, 57~60